Estrella Immunopharma, Inc. (ESLA) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is led by CEO Cheng Liu, publicly traded since 2021.
Estrella Immunopharma, Inc. (ESLA) stock trades at $0.99 with a market capitalization of $42.85M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.23, reflecting a net loss over the last twelve months, a negative price-to-book of -3.18, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.24 and $3.15, and currently trades 68.6% below its 52-week high.
On profitability, Estrella Immunopharma, Inc. generates a return on equity (ROE) of 121.72%, above the typical market range of roughly 12-15%, return on capital employed of 131.75%.
Estrella Immunopharma, Inc. by the numbers, 2020–2025
Between 2020 and 2025 Estrella Immunopharma, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-13.0M.
On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-10.0M.
Borrowings stand at $0, cash from operations was $-2.0M in the latest year, positive in 0 of the last 6.
Return on equity has averaged -0.5% over five years, and was 130.0% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Estrella Immunopharma, Inc. (ESLA) — frequently asked questions
What is Estrella Immunopharma, Inc. (ESLA) stock price today?
Estrella Immunopharma, Inc. (ESLA) is currently trading at $0.99, up 35.53% today.
What is ESLA P/E ratio?
Estrella Immunopharma, Inc.'s P/E ratio is -2.23. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is ESLA return on equity (ROE)?
Estrella Immunopharma, Inc.'s return on equity (ROE) is 121.72%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.
What is Estrella Immunopharma, Inc.'s market cap?
Estrella Immunopharma, Inc. has a market capitalization of $42.85M.
Does ESLA pay a dividend?
Estrella Immunopharma, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does ESLA carry?
Estrella Immunopharma, Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is ESLA's profit margin?
Estrella Immunopharma, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is ESLA in?
Estrella Immunopharma, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is ESLA listed on?
Estrella Immunopharma, Inc. trades on NASDAQ under the ticker ESLA.
What is ESLA's 52-week range?
Over the last year Estrella Immunopharma, Inc. has traded between $0.24 and $3.15.
Related Healthcare Stocks
Popular Stocks
Screens ESLA currently matches
On the figures above, Estrella Immunopharma, Inc. passes the filters for 5 of our ready-made screens, among them Day Gainers Stocks, Penny Stocks, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.